Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.

Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA.

Popul Health Metr. 2007 Oct 29;5:11.

2.

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U.

GMS Health Technol Assess. 2010 Apr 27;6:Doc05. doi: 10.3205/hta000083.

4.

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors.

Damm O, Nocon M, Roll S, Vauth C, Willich S, Greiner W.

GMS Health Technol Assess. 2009 Mar 11;5:Doc04. doi: 10.3205/hta000066.

5.

Multiparameter calibration of a natural history model of cervical cancer.

Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ.

Am J Epidemiol. 2007 Jul 15;166(2):137-50. Epub 2007 May 25.

PMID:
17526866
6.

A Mathematical Model of Human Papillomavirus (HPV) in the United States and its Impact on Cervical Cancer.

Lee SL, Tameru AM.

J Cancer. 2012;3:262-8. doi: 10.7150/jca.4161. Epub 2012 Jun 9.

7.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

8.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
10.

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

Kim JJ, Wright TC, Goldie SJ.

J Natl Cancer Inst. 2005 Jun 15;97(12):888-95.

PMID:
15956650
11.
12.

Estimating the long-term clinical impact of cervical cancer vaccination in Taiwan.

Yen MS, You SL, Ferko N, Debicki D, Chen YC, Chou CY.

Int J Gynecol Cancer. 2009 Feb;19(2):281-8. doi: 10.1111/IGC.0b013e31819c14d6. Erratum in: Int J Gynecol Cancer. 2009 Aug;19(6):1153. You, Shan-Lin [corrected to You, San-Lin].

PMID:
19396010
14.

Trade-offs in cervical cancer prevention: balancing benefits and risks.

Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ.

Arch Intern Med. 2008 Sep 22;168(17):1881-9. doi: 10.1001/archinte.168.17.1881.

15.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

16.

Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.

Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V.

Pharmacoeconomics. 2011 Sep;29(9):781-806. doi: 10.2165/11586560-000000000-00000.

PMID:
21838332
17.

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.

Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E.

Int J Cancer. 2003 Oct 10;106(6):896-904.

18.

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.

Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ.

Br J Cancer. 2008 Jul 22;99(2):230-8. doi: 10.1038/sj.bjc.6604462. Epub 2008 Jul 8.

19.

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.

Arch Med Res. 2009 Aug;40(6):503-13. doi: 10.1016/j.arcmed.2009.08.004.

PMID:
19853192
20.

Identifying best-fitting inputs in health-economic model calibration: a Pareto frontier approach.

Enns EA, Cipriano LE, Simons CT, Kong CY.

Med Decis Making. 2015 Feb;35(2):170-82. doi: 10.1177/0272989X14528382. Epub 2014 May 5.

Supplemental Content

Support Center